Rigel Pharmaceuticals is a clinical-stage drug development company engaged in the discovery and development of novel, small-molecule drugs to treat inflammatory and autoimmune diseases and muscle disorders. The company’s groundbreaking research is focused on intracellular signaling pathways and related targets that are critical to disease mechanisms, and Rigel’s productivity has brought about strategic collaborations with large pharmaceutical partners to develop and market its product candidates. For more information, visit the company’s Web site at www.rigel.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: